close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Aura Biosciences, Inc. - Common Stock (NQ:AURA)

7.420 +0.240 (+3.34%)
Streaming Delayed Price Updated: 10:42 AM EDT, Aug 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aura Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 Next >
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
It's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning. 
Via InvestorPlace
News headline image
Sanmina, Adtran, Ameresco And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
U.S. stock futures traded lower this morning on Tuesday. Here are some big stocks recording losses in today’s pre-market trading session. 
Via Benzinga
News headline image
Aura Biosciences Announces Pricing of Public Offering of Common Stock
From Aura Biosciences, Inc.
Via Business Wire
News headline image
Recap: Aura Biosciences Q1 Earnings ↗
 
Via Benzinga
News headline image
Aura Biosciences Releases Data Presentation Of Eye Cancer Candidate ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's After-Market Session ↗
 
Via Benzinga
News headline image
Aura Biosciences Announces Proposed Public Offering of Common Stock
From Aura Biosciences, Inc.
Via Business Wire
News headline image
Aura Biosciences Receives FDA Agreement Under Special Protocol Assessment (SPA) for CoMpass Phase 3 Clinical Trial of Belzupacap Sarotalocan (Bel-sar) in Early-stage Choroidal Melanoma
From Aura Biosciences, Inc.
Via Business Wire
News headline image
Why Shares of Aura Biosciences Jumped This Week ↗
The clinical-stage biotech may be ready to release updated phase 3 trial results on its lead therapy. 
Via The Motley Fool
News headline image
Top 5 Health Care Stocks That May Fall Off A Cliff This Month ↗
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
News headline image
Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023
From Aura Biosciences Inc.
Via Business Wire
News headline image
Aura Biosciences Strengthens and Expands Leadership Team with Key Appointments
From Aura Biosciences Inc.
Via Business Wire
News headline image
Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023 ↗
 
Via Benzinga
News headline image
Aura Biosciences to Participate in Upcoming Investor Conferences
From Aura Biosciences Inc.
Via Business Wire
News headline image
Aura Biosciences to Participate in the JMP Securities Life Sciences Conference
From Aura Biosciences Inc.
Via Business Wire
News headline image
Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences Inc.
Via Business Wire
News headline image
Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences Inc.
Via Business Wire
News headline image
Aura Biosciences Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration
From Aura Biosciences, Inc.
Via Business Wire
News headline image
Aura Biosciences to Participate in Upcoming Investor Conferences
From Aura Biosciences Inc.
Via Business Wire
News headline image
$49.5 Million Bet On Howard Hughes? Check Out These 4 Stocks Insiders Are Buying ↗
Although US stocks closed mostly lower on Wednesday, there were a few notable insider trades. 
Via Benzinga
News headline image
Why Dollar General Shares Are Trading Lower By Over 8%? Here Are 60 Stocks Moving In Thursday's Mid-Day Session ↗
Gainers Top Ships Inc. (NASDAQ: TOPS) shares jumped 74% to $5.24. Vapotherm, Inc. (NASDAQ: VAPO) gained 48.8% to $1.3250. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Aura Biosciences Announces Pricing of Public Offering of Common Stock
From Aura Biosciences, Inc.
Via Business Wire
News headline image
Aura Biosciences Announces Proposed Public Offering of Common Stock
From Aura Biosciences, Inc.
Via Business Wire
News headline image
Aura Biosciences Reports Third Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
From Aura Biosciences
Via Business Wire
News headline image
Aura Announces Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma
From Aura Biosciences, Inc.
Via Business Wire
News headline image
Aura Biosciences to Participate in Upcoming Investor Conferences
From Aura Biosciences Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at /week.